Welcome to our dedicated page for Vaxcyte SEC filings (Ticker: PCVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing loaded with immunology terms, serotype tables, and manufacturing risk factors is daunting—especially when Vaxcyte’s pipeline spans VAX-24, VAX-31, and multiple pre-clinical vaccine programs. If you have ever searched “Vaxcyte SEC filings explained simply” or wondered how insider grants line up with clinical data releases, you know the challenge. Our platform tackles that head-on, transforming every PCVX disclosure into clear language the moment it hits EDGAR.
Stock Titan’s AI parses each 10-K annual report and delivers a “Vaxcyte annual report 10-K simplified” brief that surfaces cash runway, BARDA-style funding terms, and manufacturing scale-up costs. Quarterly updates are just as direct—our “Vaxcyte quarterly earnings report 10-Q filing” synopsis highlights R&D spend versus milestone payouts, giving you an instant earnings report filing analysis. Material announcements come through 8-K filings; we flag trial read-outs and partnership agreements in plain English, so “Vaxcyte 8-K material events explained” is more than a promise.
Need real-time executive data? Toggle Form 4 alerts to track “Vaxcyte insider trading Form 4 transactions” and monitor “Vaxcyte executive stock transactions Form 4” before the market reacts. For governance insights, dive into the “Vaxcyte proxy statement executive compensation” summary where our AI links stock-option grants to pipeline milestones. Every filing—from confidential S-1 amendments to clinical hold correspondence—is covered, with natural-language answers to queries like “understanding Vaxcyte SEC documents with AI” or “where is the latest Vaxcyte Form 4 insider transactions real-time?”. Save hours, see key numbers sooner, and make informed calls on one of the most watched vaccine innovators.
Vaxcyte (PCVX) reported Q3 2025 financial results. The company posted a net loss of $212.8 million, driven by higher operating expenses as R&D rose to $209.9 million and G&A reached $32.4 million. Year-to-date, net loss was $520.1 million.
Liquidity remains strong with $2.67 billion in cash, cash equivalents and investments as of September 30, 2025 (cash and cash equivalents $281.1 million, short‑term investments $1.43 billion, long‑term investments $959.3 million). Operating cash use totaled $430.7 million for the first nine months.
Vaxcyte expanded manufacturing capacity and supply: it maintains a long‑term arrangement with Lonza and, on September 24, 2025, entered a 15‑year commercial manufacturing agreement with Thermo Fisher for drug product. Non‑cancelable purchase commitments to key manufacturing partners totaled $631.7 million. Shares outstanding were 130,029,111 at September 30, 2025 and 130,906,263 at October 31, 2025.
Vaxcyte, Inc. (PCVX) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and incorporated by reference.
The company states the information in Items 2.02 and 9.01, including Exhibit 99.1, is furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act. Vaxcyte’s common stock trades on The Nasdaq Stock Market LLC under the symbol PCVX.
Elvia Cowan, SVP Finance at Vaxcyte, Inc. (PCVX), reported the disposition of 482 shares of the issuer's common stock on 09/08/2025 at a reported price of $32.41 per share. The filing shows 26,156 shares were beneficially owned by the reporting person after the transaction and identifies the ownership form as direct.
The form explains these 482 shares were surrendered to the company to satisfy tax-withholding obligations arising when restricted stock units vested. The Form 4 was signed on behalf of Elvia Cowan by an attorney-in-fact on 09/10/2025.
Harpreet S. Dhaliwal, listed as Chief Technical Ops Officer and a director/officer of Vaxcyte, Inc. (PCVX), reported the surrender of 1,204 shares of common stock on 09/08/2025. The transaction is coded "F" and reflects shares surrendered to the issuer to cover tax withholding obligations arising from the vesting of restricted stock units (RSUs). The reported price per share for the disposition is $32.41. Following the transaction, Dhaliwal beneficially owned 33,670 shares, held directly. The Form 4 was signed on behalf of Dhaliwal by an attorney-in-fact on 09/10/2025. The filing was made by a single reporting person.
Vaxcyte, Inc. (PCVX) insider change: Chief Operating Officer Wassil Jim reported transactions dated 09/08/2025 showing a disposition of 2,759 shares of common stock at $32.41 per share, recorded as surrendered shares to cover tax withholding on vested restricted stock units. After the reported transactions, the filing states the reporting person beneficially owned 141,848 shares. The filing also discloses a separate transfer: on 09/09/2025 the reporting person transferred 1,663 shares to an ex-spouse under a divorce settlement reflected as a domestic relations order, and those transferred shares will not be reported as beneficially owned in future Section 16 filings.
Insider transaction at Vaxcyte, Inc. (PCVX): The reporting person, Andrew Guggenhime (President and CFO), recorded a disposition of 2,890 shares of Vaxcyte common stock on 09/08/2025 at a price of $32.41 per share. After the transaction, Mr. Guggenhime beneficially owned 124,309 shares. The filing explains these shares were surrendered to the issuer to cover applicable tax withholding obligations arising when restricted stock units vested, indicating the transfer was related to tax withholding rather than an open-market sale. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Grant Pickering, who is both Chief Executive Officer and a director of Vaxcyte, Inc. (PCVX), reported a transaction on 09/08/2025 in a Form 4 filing. The filing shows 7,356 shares of common stock were disposed of at $32.41 per share; the explanation states these shares were surrendered to the issuer to cover tax withholding when restricted stock units vested. After the reported transaction, Mr. Pickering beneficially owned 500,908 shares directly. The filing also discloses two trusts holding 136,215 shares each for his son and daughter. The Form 4 was signed on 09/10/2025 by an attorney-in-fact.
FMR LLC and Abigail P. Johnson disclose a 10.1% beneficial stake in Vaxcyte, Inc. The Schedule 13G/A reports combined beneficial ownership of 13,132,825.71 shares of Vaxcyte common stock. FMR LLC is shown with sole voting power over 13,090,519 shares and sole dispositive power over 13,132,825.71 shares; Abigail P. Johnson is reported with sole dispositive power for the same aggregate amount. The filing states that some other persons may have rights to dividends or sale proceeds but no other single person holds more than 5% of the class. An Exhibit 99 agreement is referenced for related identification and classification details.
Elvia Cowan, SVP Finance at Vaxcyte, Inc. (PCVX) reported two dispositions on 09/02/2025 that were filed on Form 4. The reports show shares sold at $31.56 each: 242 shares and 325 shares. The filing explains these shares were surrendered to the issuer to cover tax withholding obligations arising when restricted stock units vested. After the transactions, the reporting person beneficially owned 26,963 and 26,638 shares respectively as reported on separate lines, and the Form 4 was signed by an attorney-in-fact on behalf of Ms. Cowan on 09/04/2025.
FAQ
What is the current stock price of Vaxcyte (PCVX)?
What is the market cap of Vaxcyte (PCVX)?
